Edanur Ekinci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Edanur Ekinci has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ebuzer Kalender
Faculty of Medicine, Gaziantep University, Gaziantep, Turkey
5 shared publications - Umut Elboga
Department of Nuclear Medicine, Gaziantep University Faculty of Medicine, Gaziantep
4 shared publications - Ertan Şahin
Department of Nuclear Medicine, Gaziantep University Faculty of Medicine, Üniversite Bulvarı, 27310 Şehitkamil, Gaziantep, Türkiye
3 shared publications - Buket Eren Saribaş
Faculty of Medicine, Gaziantep University, Gaziantep, Turkey
2 shared publications - Enes Yerdes
Department of Nuclear Medicine, Gaziantep University Faculty of Medicine, Gaziantep
1 shared publication - Ertan Sahin
Department of Nuclear Medicine, School of Medicine, Gaziantep University, 27410 Gaziantep, Turkey
1 shared publication
Latest Publications
- 10 August 2026
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 57 (1) , 181
Comparative Analysis of Lesion Detection and Uptake Characteristics of 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT in Gastric Cancer
- 10 August 2026
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 57 (1) , 181
Comparative Analysis of Lesion Detection and Uptake Characteristics of 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT in Gastric Cancer
- Open Access
- 16 March 2026
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 35 (2) , 85-91
Diagnostic Value of 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT in Laryngeal Cancer Staging
Diagnostic Value of 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT in Laryngeal Cancer Staging - Molecular Imaging and Radionuclide Therapy
- 16 March 2026
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 35 (2) , 85-91
Open AccessDiagnostic Value of 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT in Laryngeal Cancer Staging
Diagnostic Value of 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT in Laryngeal Cancer Staging - Molecular Imaging and Radionuclide Therapy
- Open Access
- 24 February 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (3) , 569
Efficacy of 177Lu-PSMA-617 Therapy in mCRPC Patients with Liver Metastases: Insights into Survival Outcomes and Predictors of Response
Objectives: Metastatic castration-resistant prostate cancer (mCRPC) is associated with poor prognosis, particularly in cases of liver metastases. 177Lu-PSMA-617 (commercially known as Pluvicto) is an FDA-approved radioligand therapy for mCRPC patients. This study aimed to evaluate the efficacy of 177Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients with liver metastases, focusing on progression-free survival (PFS), overall survival (OS), and factors influencing treatment response. Materials and Methods: This retrospective study included mCRPC patients (n = 32) with liver metastases treated with Lu-PSMA-617. Patient data, including prostate-specific antigen (PSA) levels, liver SUVmax values, Lutetium-PSMA therapy cycles, and survival outcomes, were collected. Kaplan–Meier survival analysis was used to calculate PFS and OS, while regression analysis was employed to identify factors associated with treatment response. Results: The median PFS and OS were 6 and 9 months, respectively. Partial regression was observed in patients with significantly lower PSA levels (median: 90.0 ng/mL, range: 22–699 ng/mL, p = 0.001) and liver SUVmax values (median: 17.9, range: 8.3–57.0, p = 0.008). A higher number of Lutetium-PSMA cycles correlated with improved treatment response (p = 0.010) and reduced liver SUVmax values (p = 0.043). Conclusions: Lu-PSMA-617 therapy is effective in managing mCRPC with liver metastases. Increased intensity of therapy exposure, reflected by a higher number of treatment cycles, is associated with a greater biochemical response, as indicated by reduced PSA levels, thereby supporting the rationale for personalized treatment strategies. These findings support the use of Lu-PSMA-617 in mCRPC patients with liver metastases, warranting further prospective studies.
- 24 February 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (3) , 569
Open AccessEfficacy of 177Lu-PSMA-617 Therapy in mCRPC Patients with Liver Metastases: Insights into Survival Outcomes and Predictors of Response
Objectives: Metastatic castration-resistant prostate cancer (mCRPC) is associated with poor prognosis, particularly in cases of liver metastases. 177Lu-PSMA-617 (commercially known as Pluvicto) is an FDA-approved radioligand therapy for mCRPC patients. This study aimed to evaluate the efficacy of 177Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients with liver metastases, focusing on progression-free survival (PFS), overall survival (OS), and factors influencing treatment response. Materials and Methods: This retrospective study included mCRPC patients (n = 32) with liver metastases treated with Lu-PSMA-617. Patient data, including prostate-specific antigen (PSA) levels, liver SUVmax values, Lutetium-PSMA therapy cycles, and survival outcomes, were collected. Kaplan–Meier survival analysis was used to calculate PFS and OS, while regression analysis was employed to identify factors associated with treatment response. Results: The median PFS and OS were 6 and 9 months, respectively. Partial regression was observed in patients with significantly lower PSA levels (median: 90.0 ng/mL, range: 22–699 ng/mL, p = 0.001) and liver SUVmax values (median: 17.9, range: 8.3–57.0, p = 0.008). A higher number of Lutetium-PSMA cycles correlated with improved treatment response (p = 0.010) and reduced liver SUVmax values (p = 0.043). Conclusions: Lu-PSMA-617 therapy is effective in managing mCRPC with liver metastases. Increased intensity of therapy exposure, reflected by a higher number of treatment cycles, is associated with a greater biochemical response, as indicated by reduced PSA levels, thereby supporting the rationale for personalized treatment strategies. These findings support the use of Lu-PSMA-617 in mCRPC patients with liver metastases, warranting further prospective studies.
- Open Access
- 23 February 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (3) , 127
Evaluation of Adrenal Metastases in Prostate Cancer Patients with [68GA]GA-PSMA PET/CT Imaging
Objectives: This study aimed to evaluate the imaging and clinical characteristics of adrenal metastases detected by [68Ga]Ga-PSMA PET/CT in prostate cancer patients, with a focus on diagnostic accuracy and prognostic implications. Specifically, we examined the correlation between adrenal lesion characteristics and prognostic markers, such as prostate-specific antigen (PSA) levels and Gleason scores. This study also assessed the diagnostic performance of PSA, standardized uptake value maximum (SUVmax), and Hounsfield Unit (HU) values in differentiating adrenal metastases from benign adrenal adenomas. Materials and Methods: This retrospective study included 44 prostate cancer patients with adrenal lesions identified using [68Ga]Ga-PSMA PET/CT between January 2020 and October 2024. The patients were categorized into two groups: benign adrenal adenomas (n = 16) and adrenal metastases (n = 28). The PET/CT imaging was performed using a 5-ring Discovery IQ PET/CT scanner with QClear reconstruction, following the injection of 2.5 MBq/kg [68Ga]Ga-PSMA ligand and a standardized uptake time of 60 min. The imaging parameters (SUVmax and HU values), clinical characteristics (PSA levels, Gleason scores, and presence of lymphadenopathy), and patient outcomes were analyzed. A ROC analysis was conducted to evaluate the diagnostic performance of these key parameters. Results: Patients with adrenal metastases had significantly higher PSA levels (mean: 45.6 ± 12.4 ng/mL vs. 18.3 ± 6.7 ng/mL; p < 0.01) and Gleason scores (median: 8 vs. 6; p < 0.01) than those with benign adenomas. SUVmax values were significantly elevated in metastatic lesions (mean: 12.8 ± 4.3 vs. 3.4 ± 1.2; p < 0.001), and HU values were also higher (mean: 45 ± 15 vs. 18 ± 10; p < 0.01). The ROC analysis revealed that SUVmax had the highest diagnostic accuracy (AUC: 0.87), followed by PSA (AUC: 0.85) and HU (AUC: 0.80). Disease progression was observed in 67.9% of metastatic cases versus 18.8% in the adenoma group (p < 0.001), and median overall survival was shorter in metastatic cases (24 months vs. 38 months; p < 0.01). Conclusions: [68Ga]Ga-PSMA PET/CT is a valuable imaging modality for distinguishing adrenal metastases from benign adenomas in prostate cancer patients. The integration of PSA, SUVmax, and HU values into diagnostic workflows enhances diagnostic precision and improves clinical decision-making. Future research should focus on the prospective validation of these findings in larger cohorts and explore artificial intelligence-based approaches for automated lesion characterization.
- 23 February 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (3) , 127
Open AccessEvaluation of Adrenal Metastases in Prostate Cancer Patients with [68GA]GA-PSMA PET/CT Imaging
Objectives: This study aimed to evaluate the imaging and clinical characteristics of adrenal metastases detected by [68Ga]Ga-PSMA PET/CT in prostate cancer patients, with a focus on diagnostic accuracy and prognostic implications. Specifically, we examined the correlation between adrenal lesion characteristics and prognostic markers, such as prostate-specific antigen (PSA) levels and Gleason scores. This study also assessed the diagnostic performance of PSA, standardized uptake value maximum (SUVmax), and Hounsfield Unit (HU) values in differentiating adrenal metastases from benign adrenal adenomas. Materials and Methods: This retrospective study included 44 prostate cancer patients with adrenal lesions identified using [68Ga]Ga-PSMA PET/CT between January 2020 and October 2024. The patients were categorized into two groups: benign adrenal adenomas (n = 16) and adrenal metastases (n = 28). The PET/CT imaging was performed using a 5-ring Discovery IQ PET/CT scanner with QClear reconstruction, following the injection of 2.5 MBq/kg [68Ga]Ga-PSMA ligand and a standardized uptake time of 60 min. The imaging parameters (SUVmax and HU values), clinical characteristics (PSA levels, Gleason scores, and presence of lymphadenopathy), and patient outcomes were analyzed. A ROC analysis was conducted to evaluate the diagnostic performance of these key parameters. Results: Patients with adrenal metastases had significantly higher PSA levels (mean: 45.6 ± 12.4 ng/mL vs. 18.3 ± 6.7 ng/mL; p < 0.01) and Gleason scores (median: 8 vs. 6; p < 0.01) than those with benign adenomas. SUVmax values were significantly elevated in metastatic lesions (mean: 12.8 ± 4.3 vs. 3.4 ± 1.2; p < 0.001), and HU values were also higher (mean: 45 ± 15 vs. 18 ± 10; p < 0.01). The ROC analysis revealed that SUVmax had the highest diagnostic accuracy (AUC: 0.87), followed by PSA (AUC: 0.85) and HU (AUC: 0.80). Disease progression was observed in 67.9% of metastatic cases versus 18.8% in the adenoma group (p < 0.001), and median overall survival was shorter in metastatic cases (24 months vs. 38 months; p < 0.01). Conclusions: [68Ga]Ga-PSMA PET/CT is a valuable imaging modality for distinguishing adrenal metastases from benign adenomas in prostate cancer patients. The integration of PSA, SUVmax, and HU values into diagnostic workflows enhances diagnostic precision and improves clinical decision-making. Future research should focus on the prospective validation of these findings in larger cohorts and explore artificial intelligence-based approaches for automated lesion characterization.
- Open Access
- 2 September 2024
- Published by Hatay Mustafa Kemal University Faculty of Medicine in Interdisciplinary Medical Journal
- Vol. 15 (52) , 96-98
Unusual finding on bone scintigraphy: Cerebral 99m-tc mdp involvement
99mTc-MDP (99mTc-methylene diphosphonate) uptake in the brain parenchyma was observed in the scintigraphic imaging of a 56 years old male patient with renal cell carcinoma (RCC), who was referred to our clinic for metastasis screening due to widespread bone pain. Uptake of 99mTc-MDP in the brain parenchyma in bone scintigraphy is a rare finding. This case is presented to reveal the causes of cerebral 99mTc-MDP involvement.
- 2 September 2024
- Published by Hatay Mustafa Kemal University Faculty of Medicine in Interdisciplinary Medical Journal
- Vol. 15 (52) , 96-98
Open AccessUnusual finding on bone scintigraphy: Cerebral 99m-tc mdp involvement
99mTc-MDP (99mTc-methylene diphosphonate) uptake in the brain parenchyma was observed in the scintigraphic imaging of a 56 years old male patient with renal cell carcinoma (RCC), who was referred to our clinic for metastasis screening due to widespread bone pain. Uptake of 99mTc-MDP in the brain parenchyma in bone scintigraphy is a rare finding. This case is presented to reveal the causes of cerebral 99mTc-MDP involvement.